Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 17/20 | 0.80 |
| ▸ | MMP13 | P45452 | 15/20 | 0.80 |
| ▸ | MMP3 | P08254 | 10/20 | 0.80 |
| ▸ | MMP1 | P03956 | 3/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | GALR3 | O60755 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.55 |
| ▸ | MMP9 | P14780 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7901562 | 0.94 | MMP2 (0.71) | MMP2MMP13MMP3MMP1KDM4E | |
| SCHEMBL7892677 | 0.90 | MMP2 (0.75) | MMP2MMP13MMP3MMP1 | |
| SCHEMBL7455836 | 0.89 | MMP2 (1.00) | MMP2MMP13MMP3MMP1MEN1 | |
| SCHEMBL7509322 | 0.89 | MMP13 (1.00) | MMP2MMP13MMP3MMP1MMP9 | |
| SCHEMBL7454031 | 0.87 | MMP2 (1.00) | MMP2MMP13MMP3MMP1MMP9 | |
| SCHEMBL7903361 | 0.86 | MMP2 (0.66) | MMP2MMP13MMP3MMP1KDM4E | |
| SCHEMBL7450983 | 0.84 | MMP2 (1.00) | MMP2MMP13MMP3MMP1LMNA | |
| SCHEMBL7513667 | 0.82 | MMP13 (0.88) | MMP2MMP13MMP3MMP1MMP9 | |
| SCHEMBL7454871 | 0.81 | MMP2 (1.00) | MMP2MMP13MMP3MMP1LMNA | |
| SCHEMBL7516039 | 0.81 | MMP2 (0.88) | MMP2MMP13MMP3MMP1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118178353-A | Bionic nano drug delivery carrier targeting chondrocytes as well as preparation method and application thereof | 国家纳米科学中心 | 2024-06-14 | — | — | CN | claimed |
| US-20090299466-A1 | Local Delivery of Matrix Metalloproteinase Inhibitors | MEDTRONIC VASCULAR, INC. (US) | 2009-12-03 | — | — | US | claimed |
| US-6197770-B1 | ENZYME INHIBITORS; ANTIARTHRITIC AGENTS; BONE DISORDERS | THE PROCTER & GAMBLE CO. | 2001-03-06 | — | — | US | claimed |
| US-12622945-B2 | Hard tissue therapeutics | ORTHOTROPHIX, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4051702-B1 | THERANOSTICS FOR HYPERTENSION INDUCED MYOCARDIAL MICROBLEEDS | CEDARS SINAI MEDICAL CENTER (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12514900-B2 | Method to identify responders to osteoarthritis therapeutics | ORTHOTROPHIX, INC. (US) | 2026-01-06 | — | — | US | disclosed |
| US-20250316378-A1 | LIQUID BIOPSY FOR DIAGNOSIS OF EARLY OSTEOARTHRITIS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2025-10-09 | — | — | US | disclosed |
| US-20250262268-A1 | Methods and Compositions for Inhibiting Viral Infection | NEW YORK UNIVERSITY | 2025-08-21 | — | — | US | disclosed |
| WO-2024229242-A2 | METHODS OF TREATING ENDOMETRIOSIS | CEDARS-SINAI MEDICAL CENTER (US) | 2024-11-07 | — | — | WO | disclosed |
| WO-2024209047-A1 | ANTIBODIES | MODIQUEST B.V. (NL) | 2024-10-10 | — | — | WO | disclosed |
| EP-4442275-A1 | ANTI-TYPE II COLLAGEN ANTIBODIES | ModiQuest B.V. (NL) | 2024-10-09 | — | — | EP | disclosed |
| EP-4051702-A1 | THERANOSTICS FOR HYPERTENSION INDUCED MYOCARDIAL MICROBLEEDS | Cedars-Sinai Medical Center (US) | 2022-09-07 | — | — | EP | disclosed |
| US-20220226433-A1 | Method to Identify Responders to Osteoarthritis Therapeutics | ORTHOTROPHIX, INC. (US) | 2022-07-21 | — | — | US | disclosed |
| WO-2022072282-A1 | METHOD TO IDENTIFY RESPONDERS TO OSTEOARTHRITIS THERAPEUTICS | ORTHOTROPHIX, INC. (US) | 2022-04-07 | — | — | WO | disclosed |
| WO-2022072156-A1 | HARD TISSUE THERAPEUTICS | ORTHOTROPHIX, INC. (US) | 2022-04-07 | — | — | WO | disclosed |
| US-20220105154-A1 | Hard Tissue Therapeutics | ORTHOTROPHIX, INC. (US) | 2022-04-07 | — | — | US | disclosed |
| US-20090299466-A1 | Local Delivery of Matrix Metalloproteinase Inhibitors | MEDTRONIC VASCULAR, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090299466-A1 | Local Delivery of Matrix Metalloproteinase Inhibitors | MEDTRONIC VASCULAR, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090299466-A1 | Local Delivery of Matrix Metalloproteinase Inhibitors | MEDTRONIC VASCULAR, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-6197770-B1 | ENZYME INHIBITORS; ANTIARTHRITIC AGENTS; BONE DISORDERS | THE PROCTER & GAMBLE CO. | 2001-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622945-B2 | Hard tissue therapeutics | ITGAM, ITGB3, ITGB1 | MMP2 378/4885MMP13 80/4885MMP3 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.